Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Fuereder

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.
Neuro-Oncology|July 4, 2024
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastasesRupert Bartsch, Anna Sophie Berghoff, Julia Furtner, et al.
The New England Journal of Medicine|June 18, 2025
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerRavindra Uppaluri, Robert I Haddad, Yungan Tao, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.
Neuro-Oncology|July 4, 2024
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastasesRupert Bartsch, Anna Sophie Berghoff, Julia Furtner, et al.
The New England Journal of Medicine|June 18, 2025
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerRavindra Uppaluri, Robert I Haddad, Yungan Tao, et al.
Pageof 8